Sionna Therapeutics to Participate in Upcoming November Investor Conferences

Core Insights - Sionna Therapeutics is focused on developing novel medicines to improve the treatment of cystic fibrosis by normalizing the function of the CFTR protein [2][4] - The company is advancing a pipeline of small molecules aimed at correcting defects caused by the F508del genetic mutation, which is significant for cystic fibrosis patients [2] Company Overview - Sionna Therapeutics is a clinical-stage biopharmaceutical company dedicated to revolutionizing cystic fibrosis treatment [2] - The company's approach involves stabilizing the nucleotide binding domain 1 (NBD1) of the CFTR protein, which is believed to be crucial for enhancing clinical outcomes and quality of life for cystic fibrosis patients [2] - Sionna is also developing complementary CFTR modulators to work synergistically with its NBD1 stabilizers [2] Investor Engagement - Sionna will participate in upcoming investor events, including the Guggenheim 2nd Annual Healthcare Innovation Conference and the Stifel 2025 Healthcare Conference [4] - Live webcasts of these presentations will be available on Sionna's Investor Relations website, with replays accessible after the events [1][4]